Hostname: page-component-586b7cd67f-2brh9 Total loading time: 0 Render date: 2024-11-25T17:54:59.630Z Has data issue: false hasContentIssue false

Pituitary tumor-transforming gene and its binding factor in endocrine cancer

Published online by Cambridge University Press:  03 December 2010

Vicki E. Smith
Affiliation:
School of Clinical and Experimental Medicine, Institute of Biomedical Research, University of Birmingham, UK.
Jayne A. Franklyn
Affiliation:
School of Clinical and Experimental Medicine, Institute of Biomedical Research, University of Birmingham, UK.
Christopher J. McCabe*
Affiliation:
School of Clinical and Experimental Medicine, Institute of Biomedical Research, University of Birmingham, UK.
*
*Corresponding author: Christopher J. McCabe, School of Clinical and Experimental Medicine, Institute of Biomedical Research, University of Birmingham, Birmingham B15 2TH, UK. Email: [email protected]

Abstract

The pituitary tumor-transforming gene (PTTG1) encodes a multifunctional protein (PTTG) that is overexpressed in numerous tumours, including pituitary, thyroid, breast and ovarian carcinomas. PTTG induces cellular transformation in vitro and tumourigenesis in vivo, and several mechanisms by which PTTG contributes to tumourigenesis have been investigated. Also known as the human securin, PTTG is involved in cell cycle regulation, controlling the segregation of sister chromatids during mitosis. This review outlines current information regarding PTTG structure, expression, regulation and function in the pathogenesis of neoplasia. Recent progress concerning the use of PTTG as a prognostic marker or therapeutic target will be considered. In addition, the PTTG binding factor (PBF), identified through its interaction with PTTG, has also been established as a proto-oncogene that is upregulated in several cancers. Current knowledge regarding PBF is outlined and its role both independently and alongside PTTG in endocrine and related cancers is discussed.

Type
Review Article
Copyright
Copyright © Cambridge University Press 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

References

1Pei, L. and Melmed, S. (1997) Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Molecular Endocrinology 11, 433-441CrossRefGoogle ScholarPubMed
2Zou, H. et al. (1999) Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science 285, 418-422CrossRefGoogle ScholarPubMed
3Hamid, T., Malik, M.T. and Kakar, S.S. (2005) Ectopic expression of PTTG1/securin promotes tumorigenesis in human embryonic kidney cells. Molecular Cancer 4, 3CrossRefGoogle ScholarPubMed
4Ramaswamy, S. et al. (2003) A molecular signature of metastasis in primary solid tumors. Nature Genetics 33, 49-54CrossRefGoogle ScholarPubMed
5Chien, W. and Pei, L. (2000) A novel binding factor facilitates nuclear translocation and transcriptional activation function of the pituitary tumor-transforming gene product. Journal of Biological Chemistry 275, 19422-19427CrossRefGoogle ScholarPubMed
6McCabe, C.J. et al. (2003) Expression of pituitary tumour transforming gene (PTTG) and fibroblast growth factor-2 (FGF-2) in human pituitary adenomas: relationships to clinical tumour behaviour. Clinical Endocrinology 58, 141-150CrossRefGoogle ScholarPubMed
7Stratford, A.L. et al. (2005) Pituitary tumor transforming gene binding factor: a novel transforming gene in thyroid tumorigenesis. Journal of Clinical Endocrinology and Metabolism 90, 4341-4349CrossRefGoogle ScholarPubMed
8Watkins, R.J. et al. (2010) Pituitary tumor transforming gene binding factor: a new gene in breast cancer. Cancer Research 70, 3739-3749CrossRefGoogle ScholarPubMed
9Dominguez, A. et al. (1998) hpttg, a human homologue of rat pttg, is overexpressed in hematopoietic neoplasms. Evidence for a transcriptional activation function of hPTTG. Oncogene 17, 2187-2193CrossRefGoogle ScholarPubMed
10Zhang, X. et al. (1999) Structure, expression, and function of human pituitary tumor-transforming gene (PTTG). Molecular Endocrinology 13, 156-166CrossRefGoogle ScholarPubMed
11Lee, I.A., Seong, C. and Choe, I.S. (1999) Cloning and expression of human cDNA encoding human homologue of pituitary tumor transforming gene. Biochemistry and Molecular Biology International 47, 891-897Google ScholarPubMed
12Kakar, S.S. and Jennes, L. (1999) Molecular cloning and characterization of the tumor transforming gene (TUTR1): a novel gene in human tumorigenesis. Cytogenetics and Cell Genetics 84, 211-216CrossRefGoogle ScholarPubMed
13Saez, C. et al. (1999) hpttg is over-expressed in pituitary adenomas and other primary epithelial neoplasias. Oncogene 18, 5473-5476CrossRefGoogle ScholarPubMed
14Hunter, J.A. et al. (2003) The relationship between pituitary tumour transforming gene (PTTG) expression and in vitro hormone and vascular endothelial growth factor (VEGF) secretion from human pituitary adenomas. European Journal of Endocrinology 148, 203-211CrossRefGoogle ScholarPubMed
15Zhang, X. et al. (1999) Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 84, 761-767CrossRefGoogle ScholarPubMed
16Heaney, A.P. et al. (2001) Transforming events in thyroid tumorigenesis and their association with follicular lesions. Journal of Clinical Endocrinology and Metabolism 86, 5025-5032CrossRefGoogle ScholarPubMed
17Boelaert, K. et al. (2003) Pituitary tumor transforming gene and fibroblast growth factor-2 expression: potential prognostic indicators in differentiated thyroid cancer. Journal of Clinical Endocrinology and Metabolism 88, 2341-2347CrossRefGoogle ScholarPubMed
18Kim, D.S. et al. (2006) Pituitary tumor-transforming gene regulates multiple downstream angiogenic genes in thyroid cancer. Journal of Clinical Endocrinology and Metabolism 91, 1119-1128CrossRefGoogle ScholarPubMed
19Heaney, A.P. et al. (2000) Expression of pituitary-tumour transforming gene in colorectal tumours. Lancet 355, 716-719CrossRefGoogle ScholarPubMed
20Kim, D.S. et al. (2007) Securin induces genetic instability in colorectal cancer by inhibiting double-stranded DNA repair activity. Carcinogenesis 28, 749-759CrossRefGoogle ScholarPubMed
21Puri, R. et al. (2001) Molecular cloning of pituitary tumor transforming gene 1 from ovarian tumors and its expression in tumors. Cancer Letters 163, 131-139CrossRefGoogle ScholarPubMed
22Solbach, C. et al. (2004) PTTG mRNA expression in primary breast cancer: a prognostic marker for lymph node invasion and tumor recurrence. Breast 13, 80-81CrossRefGoogle ScholarPubMed
23Ogbagabriel, S. et al. (2005) Securin is overexpressed in breast cancer. Modern Pathology 18, 985-990CrossRefGoogle ScholarPubMed
24Cho-Rok, J. et al. (2006) Adenovirus-mediated transfer of siRNA against PTTG1 inhibits liver cancer cell growth in vitro and in vivo. Hepatology 43, 1042-1052Google ScholarPubMed
25Kakar, S.S. and Malik, M.T. (2006) Suppression of lung cancer with siRNA targeting PTTG. International Journal of Oncology 29, 387-395Google ScholarPubMed
26Shibata, Y. et al. (2002) Expression of PTTG (pituitary tumor transforming gene) in esophageal cancer. Japanese Journal of Clinical Oncology 32, 233-237CrossRefGoogle ScholarPubMed
27Saez, C. et al. (2002) Expression of hpttg proto-oncogene in lymphoid neoplasias. Oncogene 21, 8173-8177CrossRefGoogle ScholarPubMed
28Tfelt-Hansen, J. et al. (2004) Expression of pituitary tumor transforming gene (PTTG) and its binding protein in human astrocytes and astrocytoma cells: function and regulation of PTTG in U87 astrocytoma cells. Endocrinology 145, 4222-4231CrossRefGoogle ScholarPubMed
29Prezant, T.R., Kadioglu, P. and Melmed, S. (1999) An intronless homolog of human proto-oncogene hPTTG is expressed in pituitary tumors: evidence for hPTTG family. Journal of Clinical Endocrinology and Metabolism 84, 1149-1152CrossRefGoogle ScholarPubMed
30Chen, L. et al. (2000) Identification of the human pituitary tumor transforming gene (hPTTG) family: molecular structure, expression, and chromosomal localization. Gene 248, 41-50CrossRefGoogle ScholarPubMed
31Heaney, A.P. et al. (1999) Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis. Nature Medicine 5, 1317-1321CrossRefGoogle ScholarPubMed
32Yin, H. et al. (2001) Strain difference in regulation of pituitary tumor transforming gene (PTTG) in estrogen-induced pituitary tumorigenesis in rats. Japanese Journal of Cancer Research 92, 1034-1040CrossRefGoogle ScholarPubMed
33Marqusee, E. et al. (2000) The effect of droloxifene and estrogen on thyroid function in postmenopausal women. Journal of Clinical Endocrinology and Metabolism 85, 4407-4410Google ScholarPubMed
34Pei, L. (1998) Genomic organization and identification of an enhancer element containing binding sites for multiple proteins in rat pituitary tumor-transforming gene. Journal of Biological Chemistry 273, 5219-5225CrossRefGoogle ScholarPubMed
35Kakar, S.S. (1999) Molecular cloning, genomic organization, and identification of the promoter for the human pituitary tumor transforming gene (PTTG). Gene 240, 317-324CrossRefGoogle ScholarPubMed
36Wang, Z. and Melmed, S. (2000) Characterization of the murine pituitary tumor transforming gene (PTTG) and its promoter. Endocrinology 141, 763-771CrossRefGoogle ScholarPubMed
37Clem, A.L., Hamid, T. and Kakar, S.S. (2003) Characterization of the role of Sp1 and NF-Y in differential regulation of PTTG/securin expression in tumor cells. Gene 322, 113-121CrossRefGoogle ScholarPubMed
38Zhou, Y. et al. (2003) DNA damage-induced inhibition of securin expression is mediated by p53. Journal of Biological Chemistry 278, 462-470CrossRefGoogle ScholarPubMed
39Chen, R.N. et al. (2008) Thyroid hormone receptors suppress pituitary tumor transforming gene 1 activity in hepatoma. Cancer Research 68, 1697-1706CrossRefGoogle ScholarPubMed
40Rajamannan, N.M. et al. (2007) TGFbeta inducible early gene-1 (TIEG1) and cardiac hypertrophy: Discovery and characterization of a novel signaling pathway. Journal of Cellular Biochemistry 100, 315-325CrossRefGoogle ScholarPubMed
41Zhou, C. et al. (2008) Oct-1 induces pituitary tumor transforming gene expression in endocrine tumors. Endocrine-related Cancer 15, 817-831CrossRefGoogle ScholarPubMed
42Zhou, C. et al. (2005) Overexpression of human pituitary tumor transforming gene (hPTTG), is regulated by beta-catenin /TCF pathway in human esophageal squamous cell carcinoma. International Journal of Cancer 113, 891-898CrossRefGoogle ScholarPubMed
43Hlubek, F. et al. (2006) Securin (hPTTG1) expression is regulated by beta-catenin/TCF in human colorectal carcinoma. British Journal of Cancer 94, 1672-1677CrossRefGoogle ScholarPubMed
44Pan, H. et al. (2007) Aberrant activation of gamma-catenin promotes genomic instability and oncogenic effects during tumor progression. Cancer Biology and Therapy 6, 1638-1643CrossRefGoogle ScholarPubMed
45Thompson, A.D. III and Kakar, S.S. (2005) Insulin and IGF-1 regulate the expression of the pituitary tumor transforming gene (PTTG) in breast tumor cells. FEBS Letters 579, 3195-3200CrossRefGoogle ScholarPubMed
46Chamaon, K. et al. (2005) Regulation of the pituitary tumor transforming gene by insulin-like-growth factor-I and insulin differs between malignant and non-neoplastic astrocytes. Biochemical and Biophysics Research Communications 331, 86-92CrossRefGoogle ScholarPubMed
47Chamaon, K. et al. (2010) Transcripts of PTTG and growth factors bFGF and IGF-1 are correlated in pituitary adenomas. Experimental and Clinical Endocrinology and Diabetes 118, 121-126CrossRefGoogle ScholarPubMed
48Tsai, S.J. et al. (2005) Expression and functional analysis of pituitary tumor transforming gene-1 [corrected] in uterine leiomyomas. Journal of Clinical Endocrinology and Metabolism 90, 3715-3723CrossRefGoogle ScholarPubMed
49Vlotides, G. et al. (2006) Mechanisms for growth factor-induced pituitary tumor transforming gene-1 expression in pituitary folliculostellate TtT/GF cells. Molecular Endocrinology 20, 3321-3335CrossRefGoogle ScholarPubMed
50Kanakis, D. et al. (2003) Promoter mutations are no major cause of PTTG overexpression in pituitary adenomas. Clinical Endocrinology 58, 151-155CrossRefGoogle ScholarPubMed
51Hidalgo, M. et al. (2008) Methylation alterations are not a major cause of PTTG1 misregulation. BMC Cancer 8, 110CrossRefGoogle ScholarPubMed
52Li, T. et al. (2009) Histone acetyltransferase p300 regulates the expression of human pituitary tumor transforming gene (hPTTG). Journal of Genetics and Genomics 36, 335-342CrossRefGoogle ScholarPubMed
53Zur, A. and Brandeis, M. (2001) Securin degradation is mediated by fzy and fzr, and is required for complete chromatid separation but not for cytokinesis. EMBO Journal 20, 792-801CrossRefGoogle Scholar
54Sanchez-Puig, N., Veprintsev, D.B. and Fersht, A.R. (2005) Human full-length securin is a natively unfolded protein. Protein Science 14, 1410-1418CrossRefGoogle ScholarPubMed
55Csizmok, V. et al. (2008) Structural and dynamic characterization of intrinsically disordered human securin by NMR spectroscopy. Journal of the American Chemical Society 130, 16873-16879CrossRefGoogle ScholarPubMed
56Yu, R. et al. (2000) Pituitary tumor transforming gene (PTTG) regulates placental JEG-3 cell division and survival: evidence from live cell imaging. Molecular Endocrinology 14, 1137-1146CrossRefGoogle ScholarPubMed
57Ramos-Morales, F. et al. (2000) Cell cycle regulated expression and phosphorylation of hpttg proto-oncogene product. Oncogene 19, 403-409CrossRefGoogle ScholarPubMed
58Boelaert, K. et al. (2004) PTTG's C-terminal PXXP motifs modulate critical cellular processes in vitro. Journal of Molecular Endocrinology 33, 663-677CrossRefGoogle ScholarPubMed
59Romero, F. et al. (2001) Human securin, hPTTG, is associated with Ku heterodimer, the regulatory subunit of the DNA-dependent protein kinase. Nucleic Acids Research 29, 1300-1307CrossRefGoogle ScholarPubMed
60Mu, Y.M. et al. (2003) Human pituitary tumor transforming gene (hPTTG) inhibits human lung cancer A549 cell growth through activation of p21(WAF1/CIP1). Endocrine Journal 50, 771-781CrossRefGoogle ScholarPubMed
61Yu, R. et al. (2003) Overexpressed pituitary tumor-transforming gene causes aneuploidy in live human cells. Endocrinology 144, 4991-4998CrossRefGoogle ScholarPubMed
62Minematsu, T. et al. (2007) PTTG is a secretory protein in human pituitary adenomas and in mouse pituitary tumor cell lines. Endocrine Pathology 18, 8-15CrossRefGoogle ScholarPubMed
63Nasmyth, K. (2002) Segregating sister genomes: the molecular biology of chromosome separation. Science 297, 559-565CrossRefGoogle ScholarPubMed
64Waizenegger, I.C. et al. (2000) Two distinct pathways remove mammalian cohesin from chromosome arms in prophase and from centromeres in anaphase. Cell 103, 399-410CrossRefGoogle ScholarPubMed
65Losada, A., Hirano, M. and Hirano, T. (2002) Cohesin release is required for sister chromatid resolution, but not for condensin-mediated compaction, at the onset of mitosis. Genes and Development 16, 3004-3016CrossRefGoogle Scholar
66Sumara, I. et al. (2002) The dissociation of cohesin from chromosomes in prophase is regulated by Polo-like kinase. Molecular Cell 9, 515-525CrossRefGoogle ScholarPubMed
67Peters, J.M. (2006) The anaphase promoting complex/cyclosome: a machine designed to destroy. Nature Reviews. Molecular Cell Biology 7, 644-656CrossRefGoogle ScholarPubMed
68Jallepalli, P.V. et al. (2001) Securin is required for chromosomal stability in human cells. Cell 105, 445-457CrossRefGoogle ScholarPubMed
69Stemmann, O. et al. (2001) Dual inhibition of sister chromatid separation at metaphase. Cell 107, 715-726CrossRefGoogle ScholarPubMed
70Gorr, I.H., Boos, D. and Stemmann, O. (2005) Mutual inhibition of separase and Cdk1 by two-step complex formation. Molecular Cell 19, 135-141CrossRefGoogle ScholarPubMed
71Holland, A.J. and Taylor, S.S. (2006) Cyclin-B1-mediated inhibition of excess separase is required for timely chromosome disjunction. Journal of Cell Science 119, 3325-3336CrossRefGoogle ScholarPubMed
72Baumgarten, A.J., Felthaus, J. and Wasch, R. (2009) Strong inducible knockdown of APC/CCdc20 does not cause mitotic arrest in human somatic cells. Cell Cycle 8, 643-646CrossRefGoogle Scholar
73Kim, H.S. et al. (2009) Functional interaction between BubR1 and securin in an anaphase-promoting complex/cyclosomeCdc20-independent manner. Cancer Research 69, 27-36CrossRefGoogle Scholar
74Tong, Y. et al. (2007) Pituitary tumor transforming gene interacts with Sp1 to modulate G1/S cell phase transition. Oncogene 26, 5596-5605CrossRefGoogle ScholarPubMed
75Marangos, P. and Carroll, J. (2008) Securin regulates entry into M-phase by modulating the stability of cyclin B. Nat Cell Biol 10, 445-451CrossRefGoogle ScholarPubMed
76Yu, R. et al. (2000) Pituitary tumor transforming gene causes aneuploidy and p53-dependent and p53-independent apoptosis. Journal of Biological Chemistry 275, 36502-36505CrossRefGoogle ScholarPubMed
77Hagting, A. et al. (2002) Human securin proteolysis is controlled by the spindle checkpoint and reveals when the APC/C switches from activation by Cdc20 to Cdh1. J Cell Biol 157, 1125-1137CrossRefGoogle ScholarPubMed
78Winnepenninckx, V. et al. (2006) Expression and possible role of hPTTG1/securin in cutaneous malignant melanoma. Modern Pathology 19, 1170-1180CrossRefGoogle ScholarPubMed
79Kim, D. et al. (2005) Pituitary tumour transforming gene (PTTG) induces genetic instability in thyroid cells. Oncogene 24, 4861-4866CrossRefGoogle ScholarPubMed
80Wang, Z., Yu, R. and Melmed, S. (2001) Mice lacking pituitary tumor transforming gene show testicular and splenic hypoplasia, thymic hyperplasia, thrombocytopenia, aberrant cell cycle progression, and premature centromere division. Molecular Endocrinology 15, 1870-1879CrossRefGoogle ScholarPubMed
81Mei, J., Huang, X. and Zhang, P. (2001) Securin is not required for cellular viability, but is required for normal growth of mouse embryonic fibroblasts. Curr Biol 11, 1197-1201CrossRefGoogle Scholar
82Pfleghaar, K. et al. (2005) Securin is not required for chromosomal stability in human cells. PLoS Biol 3, e416CrossRefGoogle Scholar
83Huang, X. et al. (2005) Securin and separase phosphorylation act redundantly to maintain sister chromatid cohesion in mammalian cells. Mol Biol Cell 16, 4725-4732CrossRefGoogle ScholarPubMed
84Tong, Y. et al. (2008) Pituitary tumor transforming gene 1 regulates Aurora kinase A activity. Oncogene 27, 6385-6395CrossRefGoogle ScholarPubMed
85Wang, Z. et al. (2003) Pituitary tumor transforming gene-null male mice exhibit impaired pancreatic beta cell proliferation and diabetes. Proceedings of the National Academy of Sciences of the United States of America 100, 3428-3432CrossRefGoogle ScholarPubMed
86Chesnokova, V. et al. (2009) Diminished pancreatic beta-cell mass in securin-null mice is caused by beta-cell apoptosis and senescence. Endocrinology 150, 2603-2610CrossRefGoogle ScholarPubMed
87Vousden, K.H. (2006) Outcomes of p53 activation–spoilt for choice. Journal of Cell Science 119, 5015-5020CrossRefGoogle ScholarPubMed
88Hamid, T. and Kakar, S.S. (2004) PTTG/securin activates expression of p53 and modulates its function. Molecular Cancer 3, 18CrossRefGoogle ScholarPubMed
89Bernal, J.A. et al. (2002) Human securin interacts with p53 and modulates p53-mediated transcriptional activity and apoptosis. Nature Genetics 32, 306-311CrossRefGoogle ScholarPubMed
90Lai, Y. et al. (2007) The important anti-apoptotic role and its regulation mechanism of PTTG1 in UV-induced apoptosis. Journal of Biochemistry and Molecular Biology 40, 966-972Google ScholarPubMed
91Kho, P.S. et al. (2004) p53-regulated transcriptional program associated with genotoxic stress-induced apoptosis. Journal of Biological Chemistry 279, 21183-21192CrossRefGoogle ScholarPubMed
92Romero, F. et al. (2004) Securin is a target of the UV response pathway in mammalian cells. Molecular and Cellular Biology 24, 2720-2733CrossRefGoogle ScholarPubMed
93Limon-Mortes, M.C. et al. (2008) UV-induced degradation of securin is mediated by SKP1-CUL1-beta TrCP E3 ubiquitin ligase. Journal of Cell Science 121, 1825-1831CrossRefGoogle ScholarPubMed
94Bernal, J.A. et al. (2008) Proliferative potential after DNA damage and non-homologous end joining are affected by loss of securin. Cell Death and Differentiation 15, 202-212CrossRefGoogle ScholarPubMed
95Wang, Z. and Melmed, S. (2000) Pituitary tumor transforming gene (PTTG) transforming and transactivation activity. Journal of Biological Chemistry 275, 7459-7461CrossRefGoogle ScholarPubMed
96Ishikawa, H. et al. (2001) Human pituitary tumor-transforming gene induces angiogenesis. Journal of Clinical Endocrinology and Metabolism 86, 867-874Google ScholarPubMed
97McCabe, C.J. et al. (2002) Vascular endothelial growth factor, its receptor KDR/Flk-1, and pituitary tumor transforming gene in pituitary tumors. Journal of Clinical Endocrinology and Metabolism 87, 4238-4244CrossRefGoogle ScholarPubMed
98Fujii, T. et al. (2006) Overexpression of pituitary tumor transforming gene 1 in HCC is associated with angiogenesis and poor prognosis. Hepatology 43, 1267-1275CrossRefGoogle ScholarPubMed
99Wang, Y.K. et al. (2004) [Expression of pituitary tumor-transforming gene in endometrial carcinoma]. Zhonghua Fu Chan Ke Za Zhi 39, 538-542Google ScholarPubMed
100Minematsu, T. et al. (2006) PTTG overexpression is correlated with angiogenesis in human pituitary adenomas. Endocrine Pathology 17, 143-153CrossRefGoogle ScholarPubMed
101Kim, D.S. et al. (2006) Pituitary tumor transforming gene (PTTG) stimulates thyroid cell proliferation via a vascular endothelial growth factor/kinase insert domain receptor/inhibitor of DNA binding-3 autocrine pathway. Journal of Clinical Endocrinology and Metabolism 91, 4603-4611CrossRefGoogle Scholar
102Malik, M.T. and Kakar, S.S. (2006) Regulation of angiogenesis and invasion by human Pituitary tumor transforming gene (PTTG) through increased expression and secretion of matrix metalloproteinase-2 (MMP-2). Molecular Cancer 5, 61CrossRefGoogle ScholarPubMed
103Horwitz, G.A. et al. (2003) Human pituitary tumor-transforming gene (PTTG1) motif suppresses prolactin expression. Molecular Endocrinology 17, 600-609CrossRefGoogle ScholarPubMed
104Pei, L. (2001) Identification of c-myc as a down-stream target for pituitary tumor-transforming gene. Journal of Biological Chemistry 276, 8484-8491CrossRefGoogle ScholarPubMed
105Pei, L. (1999) Pituitary tumor-transforming gene protein associates with ribosomal protein S10 and a novel human homologue of DnaJ in testicular cells. Journal of Biological Chemistry 274, 3151-3158CrossRefGoogle Scholar
106Tong, Y. and Eigler, T. (2009) Transcriptional targets for pituitary tumor-transforming gene-1. Journal of Molecular Endocrinology 43, 179-185CrossRefGoogle ScholarPubMed
107Yaspo, M.L. et al. (1998) Cloning of a novel human putative type Ia integral membrane protein mapping to 21q22.3. Genomics 49, 133-136CrossRefGoogle ScholarPubMed
108Bork, P. et al. (1999) Domains in plexins: links to integrins and transcription factors. Trends in Biochemical Sciences 24, 261-263CrossRefGoogle ScholarPubMed
109Stock, M. et al. (2004) Identification of novel genes of the bone-specific transcription factor Runx2. Journal of Bone and Mineral Research 19, 959-972CrossRefGoogle ScholarPubMed
110Smith, V.E. et al. (2009) A novel mechanism of sodium iodide symporter repression in differentiated thyroid cancer. Journal of Cell Science 122, 3393-3402CrossRefGoogle ScholarPubMed
111Filippella, M. et al. (2006) Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study. Clinical Endocrinology 65, 536-543CrossRefGoogle ScholarPubMed
112Wierinckx, A. et al. (2007) A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumors. Endocrine-related Cancer 14, 887-900CrossRefGoogle ScholarPubMed
113Raverot, G. et al. (2010) Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up. Journal of Clinical Endocrinology and Metabolism 95, 1708-1716CrossRefGoogle ScholarPubMed
114Noh, T.W. et al. (2009) Predicting recurrence of nonfunctioning pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 94, 4406-4413CrossRefGoogle ScholarPubMed
115Chesnokova, V. et al. (2005) Pituitary hypoplasia in Pttg−/− mice is protective for Rb+/− pituitary tumorigenesis. Molecular Endocrinology 19, 2371-2379CrossRefGoogle ScholarPubMed
116Chesnokova, V. et al. (2007) Senescence mediates pituitary hypoplasia and restrains pituitary tumor growth. Cancer Research 67, 10564-10572CrossRefGoogle ScholarPubMed
117Chesnokova, V. et al. (2008) p21(Cip1) restrains pituitary tumor growth. Proceedings of the National Academy of Sciences of the United States of America 105, 17498-17503CrossRefGoogle ScholarPubMed
118Hsu, Y.H. et al. (2010) Overexpression of the pituitary tumor transforming gene induces p53-dependent senescence through activating DNA damage response pathway in normal human fibroblasts. Journal of Biological Chemistry 285, 22630-22638CrossRefGoogle ScholarPubMed
119Abbud, R.A. et al. (2005) Early multipotential pituitary focal hyperplasia in the alpha-subunit of glycoprotein hormone-driven pituitary tumor-transforming gene transgenic mice. Molecular Endocrinology 19, 1383-1391CrossRefGoogle ScholarPubMed
120Donangelo, I. et al. (2006) Pituitary tumor transforming gene overexpression facilitates pituitary tumor development. Endocrinology 147, 4781-4791CrossRefGoogle ScholarPubMed
121Zhou, C. et al. (2009) E2F1 induces pituitary tumor transforming gene (PTTG1) expression in human pituitary tumors. Molecular Endocrinology 23, 2000-2012CrossRefGoogle ScholarPubMed
122Heaney, A.P., Fernando, M. and Melmed, S. (2002) Functional role of estrogen in pituitary tumor pathogenesis. Journal of Clinical Investigation 109, 277-283CrossRefGoogle ScholarPubMed
123Saez, C. et al. (2006) Prognostic significance of human pituitary tumor-transforming gene immunohistochemical expression in differentiated thyroid cancer. Journal of Clinical Endocrinology and Metabolism 91, 1404-1409CrossRefGoogle ScholarPubMed
124Ying, H. et al. (2006) Aberrant accumulation of PTTG1 induced by a mutated thyroid hormone beta receptor inhibits mitotic progression. Journal of Clinical Investigation 116, 2972-2984CrossRefGoogle ScholarPubMed
125Kim, C.S. et al. (2007) The pituitary tumor-transforming gene promotes angiogenesis in a mouse model of follicular thyroid cancer. Carcinogenesis 28, 932-939CrossRefGoogle Scholar
126Boelaert, K. et al. (2007) PTTG and PBF repress the human sodium iodide symporter. Oncogene 26, 4344-4356CrossRefGoogle ScholarPubMed
127Chen, G. et al. (2004) Inhibitory effects of anti-sense PTTG on malignant phenotype of human ovarian carcinoma cell line SK-OV-3. Journal of Huazhong University of Science and Technology. Medical Sciences 24, 369-372Google ScholarPubMed
128El Naggar, S.M. et al. (2007) Development of cystic glandular hyperplasia of the endometrium in Mullerian inhibitory substance type II receptor-pituitary tumor transforming gene transgenic mice. Journal of Endocrinology 194, 179-191CrossRefGoogle ScholarPubMed
129Talvinen, K. et al. (2008) Proliferation marker securin identifies favourable outcome in invasive ductal breast cancer. British Journal of Cancer 99, 335-340CrossRefGoogle ScholarPubMed
130Talvinen, K. et al. (2009) Securin promotes the identification of favourable outcome in invasive breast cancer. British Journal of Cancer 101, 1005-1010CrossRefGoogle ScholarPubMed
131Lo, Y.L. et al. (2007) Breast cancer risk associated with genotypic polymorphism of the mitotic checkpoint genes: a multigenic study on cancer susceptibility. Carcinogenesis 28, 1079-1086CrossRefGoogle Scholar
132Brendle, A. et al. (2009) Single nucleotide polymorphisms in chromosomal instability genes and risk and clinical outcome of breast cancer: a Swedish prospective case-control study. European Journal of Cancer 45, 435-442CrossRefGoogle ScholarPubMed
133Chen, C.C. et al. (2006) Combination of multiple mRNA markers (PTTG1, Survivin, UbcH10 and TK1) in the diagnosis of Taiwanese patients with breast cancer by membrane array. Oncology 70, 438-446CrossRefGoogle ScholarPubMed
134Ghayad, S.E. et al. (2009) Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer. Journal of Molecular Endocrinology 42, 87-103CrossRefGoogle ScholarPubMed
135Ito, T. et al. (2008) Pituitary tumor-transforming 1 increases cell motility and promotes lymph node metastasis in esophageal squamous cell carcinoma. Cancer Research 68, 3214-3224CrossRefGoogle ScholarPubMed
136Rehfeld, N. et al. (2006) The influence of the pituitary tumor transforming gene-1 (PTTG-1) on survival of patients with small cell lung cancer and non-small cell lung cancer. Journal of Carcinogenesis 5, 4CrossRefGoogle ScholarPubMed
137El Naggar, S.M., Malik, M.T. and Kakar, S.S. (2007) Small interfering RNA against PTTG: a novel therapy for ovarian cancer. International Journal of Oncology 31, 137-143Google ScholarPubMed
138Solbach, C. et al. (2005) Pituitary tumor-transforming gene (PTTG): a novel target for anti-tumor therapy. Anticancer Research 25, 121-125Google ScholarPubMed
139Mo, Z. et al. (2009) Antitumor effect of F-PBF(beta-TrCP)-induced targeted PTTG1 degradation in HeLa cells. Journal of Biotechnology 139, 6-11CrossRefGoogle ScholarPubMed

Further reading, resources and contacts

Yu, R. and Melmed, S. (2010) Pathogenesis of pituitary tumors. Progress in Brain Research 182, 207-227CrossRefGoogle ScholarPubMed
Reynolds, L.E. et al. (2010) Tumor angiogenesis is reduced in the Tc1 mouse model of down syndrome. Nature 465, 813-817CrossRefGoogle Scholar
McCabe, C.J. (2008) Moving towards the use of targeted therapies in thyroid cancer. Nature Clinical Practice Endocrinology and Metabolism 4, 604-605CrossRefGoogle ScholarPubMed